Abstract Body

The 2014 revised CDC/APHL Guidelines for Laboratory Diagnosis of HIV infection recommend that reactive antigen/antibody (ag/ab) screening tests be followed by a supplemental antibody test capable of differentiating HIV-1 from HIV-2. However, there is currently only one such supplemental test approved and available for use in the United States. We investigated the performance of other FDA-approved single-use HIV tests when used in this step in an HIV testing algorithm.

Stored plasma or serum specimens from a study conducted in Los Angeles, California from 2003-2007 were used in this analysis. 707 specimens previously reactive on at least one FDA-approved ag/ab screening test, from 5,470 persons screened for HIV and 403 persons recruited with known HIV infection, were tested with 8 FDA-approved rapid HIV tests. We compared these test results with those from the Geenius HIV-1/HIV-2 differentiation assay. As in the guidelines, specimens with non-reactive results on the supplemental test after a reactive ag/ab test were categorized as HIV-infected or false-reactive on the screening test based on the Aptima HIV-1 qualitative RNA test result.

All FDA-approved rapid tests performed similarly to the Geenius assay in terms of ability to differentiate true infection from false-reactive results for specimens from persons without early HIV infection (Table 1). The Insti HIV-1/HIV-2 antibody test and Determine HIV-1/HIV-2 Combo correctly identified 5/8 early infection specimens; all had been non-reactive using Geenius and all other rapid tests. However, these two tests also returned reactive results in 3-4 specimens (<1/1000 screened) that were HIV-1 Western blot and Aptima negative.

All FDA-approved rapid tests could serve the role of a supplemental test in the HIV-1 diagnostic algorithm. Although they don’t differentiate HIV-1 from HIV-2, HIV-2 remains rare in the US and would be identified when a quantitative HIV-1 viral load was performed at HIV care initiation. Likewise, the few false-reactive rapid tests could also be resolved during clinical follow-up. Factors such as speed with which results can be returned and care initiated and simplicity of both testing and result reporting make these other rapid tests good alternatives for the second step in the HIV diagnostic algorithm. These data suggest other rapid tests should be considered as options for this step in future updates to laboratory testing algorithm guidelines.